TapewireFind a company

person · Reporting owner

George Jean

Disclosed activity across 7 companies

Tapewire entity
76913
SEC CIK
0001291804

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACCELERON PHARMA INCXLRN · Entity 15780DirectorJanuary 22, 2020January 24, 2020
ALX ONCOLOGY HOLDINGS INCALXO · Entity 604010% ownerDecember 13, 2021December 15, 2021
Astria Therapeutics, Inc.CATB · Entity 68888DirectorJune 07, 2018June 07, 2018
Calithera Biosciences, Inc.CALA · Entity 113073DirectorJune 11, 2021June 14, 2021
Cyteir Therapeutics, Inc.CYT · Entity 92707DirectorFebruary 14, 2024February 16, 2024
Disc Medicine, Inc.GMTX · Entity 2273Director · 10% ownerFebruary 05, 2021February 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCELERON PHARMA INC

Report date January 22, 2020 · Filed January 24, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,127 Reported balance After 2020-01-22 transaction · row 1
1 source row

Row 1 · 2020-01-22 · Grant · Acquired 1,377 · Balance 5,127

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 · Expires 2030-01-22Direct8,185 Reported balance After 2020-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-01-22 · Grant · Acquired 8,185 · Balance 8,185

F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Lightstone Ventures, L.P.2,097,326 Last balance in matching sequence After 2021-12-13 transaction · row 11 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2021-12-13 · Sale · Disposed 11,945 · Balance 2,127,969

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 3 · 2021-12-13 · Sale · Disposed 17,169 · Balance 2,110,800

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 5 · 2021-12-13 · Sale · Disposed 9,509 · Balance 2,101,291

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 7 · 2021-12-13 · Sale · Disposed 2,196 · Balance 2,099,095

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 9 · 2021-12-13 · Sale · Disposed 1,329 · Balance 2,097,766

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 11 · 2021-12-13 · Sale · Disposed 440 · Balance 2,097,326

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Lightstone Ventures (A), L.P.285,956 Last balance in matching sequence After 2021-12-13 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 2 · 2021-12-13 · Sale · Disposed 1,627 · Balance 290,131

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 4 · 2021-12-13 · Sale · Disposed 2,339 · Balance 287,792

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 6 · 2021-12-13 · Sale · Disposed 1,296 · Balance 286,496

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 8 · 2021-12-13 · Sale · Disposed 299 · Balance 286,197

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 10 · 2021-12-13 · Sale · Disposed 181 · Balance 286,016

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Row 12 · 2021-12-13 · Sale · Disposed 60 · Balance 285,956

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Lightstone Ventures II, L.P.2,023,469 Reported balance Holding disclosure · report date 2021-12-13 · row 13 Holding and transaction disclosures are not merged.
1 source row

Row 13 · Balance 2,023,469

F9: Shares are held directly by Lightstone Ventures II, L.P. ("LV II LP"). LSV Associates II, LLC (LSV Associates II), is the general partner of LV II LP and may be deemed to beneficially own the shares held by LV II LP. Michael A. Carusi, Jean M. George, Jason W. Lettmann and Henry A. Plain, Jr. are the managing directors of LSV Associates II and may be deemed to share voting and investment power over the shares held by LV II LP. Each of LSV Associates II and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Common StockSEC Table I · non-derivativeIndirectBy Lightstone Ventures II (A), L.P.120,212 Reported balance Holding disclosure · report date 2021-12-13 · row 14 Holding and transaction disclosures are not merged.
1 source row

Row 14 · Balance 120,212

F10: Shares are held directly by Lightstone Ventures II (A), L.P. ("LV II(A) LP"). LSV Associates II, is the general partner of LV II(A) LP and may be deemed to beneficially own the shares held by LV II(A) LP. Michael A. Carusi, Jean M. George, Jason W. Lettmann and Henry A. Plain, Jr. are the managing directors of LSV Associates II and may be deemed to share voting and investment power over the shares held by LV II(A) LP. Each of LSV Associates II and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares are held directly by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC (LSV Associates), is the general partner of LV LP and may be deemed to beneficially own the shares held by LV LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

F3: Shares are held directly by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP and may be deemed to beneficially own the shares held by LV(A) LP. Michael A. Carusi, Jean M. George and Henry A. Plain, Jr. are the managing directors of LSV Associates and may be deemed to share voting and investment power over the shares held by LV(A) LP. Each of LSV Associates and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: Shares are held directly by Lightstone Ventures II, L.P. ("LV II LP"). LSV Associates II, LLC (LSV Associates II), is the general partner of LV II LP and may be deemed to beneficially own the shares held by LV II LP. Michael A. Carusi, Jean M. George, Jason W. Lettmann and Henry A. Plain, Jr. are the managing directors of LSV Associates II and may be deemed to share voting and investment power over the shares held by LV II LP. Each of LSV Associates II and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

F10: Shares are held directly by Lightstone Ventures II (A), L.P. ("LV II(A) LP"). LSV Associates II, is the general partner of LV II(A) LP and may be deemed to beneficially own the shares held by LV II(A) LP. Michael A. Carusi, Jean M. George, Jason W. Lettmann and Henry A. Plain, Jr. are the managing directors of LSV Associates II and may be deemed to share voting and investment power over the shares held by LV II(A) LP. Each of LSV Associates II and Messrs. Carusi, George and Plain disclaims beneficial ownership of these shares except to the extent of its, his or her respective pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Astria Therapeutics, Inc.

Report date June 07, 2018 · Filed June 07, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2028-06-06Direct14,000 Reported balance After 2018-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-07 · Grant · Acquired 14,000 · Balance 14,000

F1: This option was granted on June 7, 2018 and is scheduled to vest on June 7, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 7, 2018 and is scheduled to vest on June 7, 2019.

Calithera Biosciences, Inc.

Report date June 11, 2021 · Filed June 14, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2031-06-10Direct20,000 Reported balance After 2021-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-06-11 · Grant · Acquired 20,000 · Balance 20,000

F1: 1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Cyteir Therapeutics, Inc.

Report date February 14, 2024 · Filed February 16, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,150 Reported balance After 2024-02-14 transaction · row 1
1 source row

Row 1 · 2024-02-14 · Exercise / conversion · Acquired 14,150 · Balance 14,150

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03Direct0 Reported balance After 2024-02-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-02-14 · Exercise / conversion · Disposed 14,150 · Balance 0

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,444,265 Reported balance Holding disclosure · report date 2024-02-14 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,444,265

F1: Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.

Disc Medicine, Inc.

Report date February 05, 2021 · Filed February 16, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote2,796,868 Reported balance Holding disclosure · report date 2021-02-05 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 2,796,868

F1: These shares are held by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC ("LSV Associates") is the general partner of LV LP. As an individual managing director of LSV Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV LP. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote381,040 Reported balance Holding disclosure · report date 2021-02-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 381,040

F2: These shares are held by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP. As an individual managing director of LSV Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,658,198 Reported balance Holding disclosure · report date 2021-02-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,658,198

F3: These shares are held by Lightstone Singapore, L.P. ("LV Singapore"), Lightstone Singapore Associates, LLC ("Lightstone Singapore Associates") is the general partner of LV Singapore. As an individual managing director of Lightstone Singapore Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV Singapore. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Lightstone Ventures, L.P. ("LV LP"). LSV Associates, LLC ("LSV Associates") is the general partner of LV LP. As an individual managing director of LSV Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV LP. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

F2: These shares are held by Lightstone Ventures (A), L.P. ("LV(A) LP"). LSV Associates is the general partner of LV(A) LP. As an individual managing director of LSV Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

F3: These shares are held by Lightstone Singapore, L.P. ("LV Singapore"), Lightstone Singapore Associates, LLC ("Lightstone Singapore Associates") is the general partner of LV Singapore. As an individual managing director of Lightstone Singapore Associates, the reporting person shares voting and dispositive power with respect to the shares held of record by LV Singapore. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SHOULDER INNOVATIONS, INC.

Report date August 01, 2025 · Filed August 05, 2025

Jointly reported with LSV Associates II, LLC, Lightstone Ventures II, L.P., Lightstone Ventures II (A), L.P., Plain Henry A JR

Section 16 reporting ended · disclosed 2025-08-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnotes1,885,136 Last balance in matching sequence After 2025-08-01 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2025-08-01 · Conversion · Acquired 1,618,470 · Balance 1,618,470

F1: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis.

F2: LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.

F3: Following the transactions reported in this Form 4, (i) 1,781,479 shares of Common Stock are held by LSV II and (ii) 103,657 shares of Common Stock are held by LSV II (A).

Row 2 · 2025-08-01 · Purchase · Acquired 266,666 · Balance 1,885,136

F2: LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.

F3: Following the transactions reported in this Form 4, (i) 1,781,479 shares of Common Stock are held by LSV II and (ii) 103,657 shares of Common Stock are held by LSV II (A).

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnotes0 Reported balance After 2025-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-08-01 · Conversion · Disposed 20,930,233 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis.

F2: LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.

F4: Consists of (i) 1,036,638 shares of Common Stock underlying Series C Preferred Stock and 492,833 shares of Common Stock underlying Series D Preferred Stock held by LSV II; and (ii) 60,333 shares of Common Stock underlying Series C Preferred Stock and 28,666 shares of Common Stock underlying Series D Preferred Stock held by LSV II (A).

Series D Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnotes0 Reported balance After 2025-08-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-08-01 · Conversion · Disposed 9,950,208 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis.

F2: LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.

F4: Consists of (i) 1,036,638 shares of Common Stock underlying Series C Preferred Stock and 492,833 shares of Common Stock underlying Series D Preferred Stock held by LSV II; and (ii) 60,333 shares of Common Stock underlying Series C Preferred Stock and 28,666 shares of Common Stock underlying Series D Preferred Stock held by LSV II (A).

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis.

F2: LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. ("LSV II") and Lightstone Ventures II (A), L.P. ("LSV II (A)") and has sole voting and dispositive power with respect to the shares held by LSV II and LSV II (A). The reporting person is a managing director of LSV Associates II, LLC, and shares voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Jean George, Michael A. Carusi and Henry A. Plain, Jr. are the managing directors of LSV Associates II, LLC, and share voting and dispositive power with respect to the shares held of record by LSV II and LSV II (A). Mr. Carusi is a director of the Issuer and files separate Section 16 reports. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his, her or its respective pecuniary interest therein.

F3: Following the transactions reported in this Form 4, (i) 1,781,479 shares of Common Stock are held by LSV II and (ii) 103,657 shares of Common Stock are held by LSV II (A).

F4: Consists of (i) 1,036,638 shares of Common Stock underlying Series C Preferred Stock and 492,833 shares of Common Stock underlying Series D Preferred Stock held by LSV II; and (ii) 60,333 shares of Common Stock underlying Series C Preferred Stock and 28,666 shares of Common Stock underlying Series D Preferred Stock held by LSV II (A).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 222,752 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · derivative · entry 8

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 222,752 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · ownership.nature: The shares are held of record by Lightstone Ventures (A), LP (LV(A) LP). LSV Associates, the General Partner of LV(A) LP, and Mr. Carusi, Ms. George and Mr. Plain, the individual managing directors of LSV Associates, share voting and dispositive power with respect to the shares held of record by LV(A) LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 1,633,743 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · derivative · entry 7

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,633,743 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · ownership.nature: The shares are held of record by Lightstone Ventures, LP (LV LP). LSV Associates, LLC (LSV Associates), the General Partner of LV LP, and Michael A. Carusi, Jean M. George and Henry A. Plain, Jr., the individual managing directors of LSV Associates, share voting and dispositive power with respect to the shares held of record by LV LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 111,528 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 6

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 120,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date

F11 · balance_after: Includes 8,684 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F10 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II(A) LP). LSV Associates II, LLC (LSV Associates II), the General Partner of LV(A) II LP, and Mr. Carusi, Ms. George, Mr. Plain and Mr. Lettmann, as the individual managing directors of LSV Associates II, share voting and dispositive power with respect to the shares held of record by LV II(A) LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 PurchaseCommon Stock 22,000 $19.00 $418,000.00
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 5

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,000

F10 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II(A) LP). LSV Associates II, LLC (LSV Associates II), the General Partner of LV(A) II LP, and Mr. Carusi, Ms. George, Mr. Plain and Mr. Lettmann, as the individual managing directors of LSV Associates II, share voting and dispositive power with respect to the shares held of record by LV II(A) LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 1,498,984 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 4

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,023,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date

F9 · balance_after: Includes 146,485 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F8 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, and Mr. Carusi, Ms. George, Mr. Plain and Jason W. Lettmann, as the individual managing directors of LSV Associates II, share voting and dispositive power with respect to the shares held of record by LV II LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 PurchaseCommon Stock 378,000 $19.00 $7,182,000.00
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 3

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 378,000

F8 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, and Mr. Carusi, Ms. George, Mr. Plain and Jason W. Lettmann, as the individual managing directors of LSV Associates II, share voting and dispositive power with respect to the shares held of record by LV II LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein. Mr. Lettmann is a director of the Issuer and files separate Section 16 reports.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 249,632 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 2

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 309,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date

F6 · balance_after: Includes 59,590 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F7 · ownership.nature: The shares are held of record by Lightstone Ventures (A), LP (LV(A) LP). LSV Associates, the General Partner of LV(A) LP, and Mr. Carusi, Ms. George and Mr. Plain, the individual managing directors of LSV Associates, share voting and dispositive power with respect to the shares held of record by LV(A) LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 16:18 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 1,831,027 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-020030 · doc4.xml · nonDerivative · entry 1

LSV Associates, LLC · CIK 0001643828 · 10% owner

Lightstone Ventures, L.P. · CIK 0001572522 · 10% owner

Lightstone Ventures (A), L.P. · CIK 0001572523 · 10% owner

Lightstone Ventures II, L.P. · CIK 0001699565 · 10% owner

Lightstone Ventures II (A), L.P. · CIK 0001706610 · 10% owner

LSV Associates II, LLC · CIK 0001818388 · 10% owner

Carusi Michael A · CIK 0001306506 · 10% owner

George Jean · CIK 0001291804 · 10% owner

Plain Henry A JR · CIK 0001384286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,268,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date

F4 · balance_after: Includes 437,060 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F5 · ownership.nature: The shares are held of record by Lightstone Ventures, LP (LV LP). LSV Associates, LLC (LSV Associates), the General Partner of LV LP, and Michael A. Carusi, Jean M. George and Henry A. Plain, Jr., the individual managing directors of LSV Associates, share voting and dispositive power with respect to the shares held of record by LV LP, but each disclaims beneficial ownership of such shares except to the extent of his, her or its individual pecuniary interest therein.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:02 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $5.25 $0.00
Disclosure

SEC source: 0000899243-20-016151 · doc4.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-06-08

F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 9, 2020, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:41 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantOption to Purchase Common Stock · Derivative 8,185 $0.00 Strike: $52.99 $0.00
Disclosure

SEC source: 0001179110-20-000775 · edgar.xml · derivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,185

Underlying: Common Stock · 8,185 shares

Expires 2030-01-22

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:41 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantCommon Stock 1,377 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-000775 · edgar.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,127

Read SEC document
June 28, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 11,812 $41.17 $486,300.04
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 7

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 40.93 to 41.37, inclusive.

F4 · ownership.nature: These securities are directly owned by ACM. The Reporting Person is a director of ACM. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionOption to Purchase Common Stock · Derivative 7,500 $0.00 Strike: $30.17 $0.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · derivative · entry 10

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2027-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date.

F3 · ownership.direct: The Reporting Person held the options and underlying shares for the benefit of ATV Capital Management, Inc. ("ACM") pursuant to ACM's policy with respect to equity compensation in respect of director service. Pursuant to the policy, the Reporting Person assigned these shares to ACM for no additional consideration.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $27.97 $0.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · derivative · entry 9

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date.

F3 · ownership.direct: The Reporting Person held the options and underlying shares for the benefit of ATV Capital Management, Inc. ("ACM") pursuant to ACM's policy with respect to equity compensation in respect of director service. Pursuant to the policy, the Reporting Person assigned these shares to ACM for no additional consideration.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionOption to Purchase Common Stock · Derivative 20,000 $0.00 Strike: $24.11 $0.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · derivative · entry 8

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2023-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant.

F3 · ownership.direct: The Reporting Person held the options and underlying shares for the benefit of ATV Capital Management, Inc. ("ACM") pursuant to ACM's policy with respect to equity compensation in respect of director service. Pursuant to the policy, the Reporting Person assigned these shares to ACM for no additional consideration.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 OtherCommon Stock 11,812 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 6

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,812

F3 · kind: The Reporting Person held the options and underlying shares for the benefit of ATV Capital Management, Inc. ("ACM") pursuant to ACM's policy with respect to equity compensation in respect of director service. Pursuant to the policy, the Reporting Person assigned these shares to ACM for no additional consideration.

F4 · ownership.nature: These securities are directly owned by ACM. The Reporting Person is a director of ACM. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 OtherCommon Stock 11,812 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 5

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

F3 · kind: The Reporting Person held the options and underlying shares for the benefit of ATV Capital Management, Inc. ("ACM") pursuant to ACM's policy with respect to equity compensation in respect of director service. Pursuant to the policy, the Reporting Person assigned these shares to ACM for no additional consideration.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 25,688 $39.16 $1,005,942.08
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 4

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,562

F1 · kind: These shares were sold to cover the exercise price of the three options reported herein.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (5) to this Form 4.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionCommon Stock 7,500 $30.17 $226,275.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 3

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionCommon Stock 10,000 $27.97 $279,700.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 26, 2019 Filed Jun 28, 2019 19:25 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionCommon Stock 20,000 $24.11 $482,200.00
Disclosure

SEC source: 0001209191-19-039550 · doc4.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 30, 2019 Filed Jun 3, 2019 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $5.42 $0.00
Disclosure

SEC source: 0000899243-19-015380 · doc4.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2029-05-29

F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 30, 2019, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Read SEC document
January 25, 2019 Filed Jan 29, 2019 17:45 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantOption to Purchase Common Stock · Derivative 7,500 $0.00 Strike: $41.64 $0.00
Disclosure

SEC source: 0001179110-19-001059 · edgar.xml · derivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2029-01-25

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Read SEC document
January 25, 2019 Filed Jan 29, 2019 17:45 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantCommon Stock 1,250 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-001059 · edgar.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Read SEC document
June 07, 2018 Filed Jun 7, 2018 18:04 UTC Astria Therapeutics, Inc. CATB · Entity 68888 GrantStock Option (right to buy) · Derivative 14,000 $0.00 Strike: $1.48 $0.00
Disclosure

SEC source: 0001179110-18-008241 · edgar.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2028-06-06

F1 · derivative.exercise_date: This option was granted on June 7, 2018 and is scheduled to vest on June 7, 2019.

Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:06 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $5.15 $0.00
Disclosure

SEC source: 0000899243-18-014884 · doc4.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2028-05-30

F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 31, 2018, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:19 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantOption to Purchase Common Stock · Derivative 7,500 $0.00 Strike: $40.61 $0.00
Disclosure

SEC source: 0001179110-18-003501 · edgar.xml · derivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-03-01

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:19 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantCommon Stock 1,250 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-003501 · edgar.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Read SEC document
December 15, 2017 Filed Dec 18, 2017 16:53 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 105,122 $35.73 $3,756,009.06
Disclosure

SEC source: 0001209191-17-066163 · doc4.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · shares: Includes 98,674 shares, 3,959 shares, 1,902 shares and 587 shares of common stock sold by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C") and ATV Entrepreneurs VII, L.P. ("ATV VII E"), respectively.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 - $36.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

F3 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
July 27, 2017 Filed Jul 28, 2017 16:03 UTC Astria Therapeutics, Inc. CATB · Entity 68888 GrantStock Option (right to buy) · Derivative 6,500 $0.00 Strike: $1.27 $0.00
Disclosure

SEC source: 0001179110-17-010769 · edgar.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2027-07-26

F1 · derivative.exercise_date: This option was granted on July 27, 2017 and is scheduled to vest in full on June 7, 2018.

Read SEC document
June 09, 2017 Filed Jun 13, 2017 16:35 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $14.20 $0.00
Disclosure

SEC source: 0000899243-17-016233 · doc4.xml · derivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2027-06-08

F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 9, 2017, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.

Read SEC document
March 02, 2017 Filed Mar 14, 2017 18:20 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantOption to Purchase Common Stock · Derivative 7,500 $0.00 Strike: $30.17 $0.00
Disclosure

SEC source: 0001179110-17-004594 · edgar.xml · derivative · entry 3

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2027-03-02

F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.

Read SEC document
March 02, 2017 Filed Mar 14, 2017 18:20 UTC ACCELERON PHARMA INC XLRN · Entity 15780 GrantCommon Stock 1,250 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-004594 · edgar.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Read SEC document
December 07, 2016 Filed Dec 19, 2016 16:05 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionWarrants to Purchase Common Stock · Derivative 127,122 $0.00 Strike: $5.88 $0.00
Disclosure

SEC source: 0001209191-16-155873 · doc4.xml · derivative · entry 3

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 127,122 shares

Expires 2020-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents 119,322 shares, 4,788 shares, 2,301 shares and 711 shares of common stock underlying warrants held by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C") and ATV Entrepreneurs VII, L.P. ("ATV VII E"), respectively. Shares ultimately received by each of these entities were net of shares withheld, as described in footnote 3, due to the net exercise of warrants.

F4 · derivative.exercise_date: The warrants to purchase common stock were exercisable at any time at the holders' election.

F1 · derivative.underlying_shares: Represents 119,322 shares, 4,788 shares, 2,301 shares and 711 shares of common stock underlying warrants held by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C") and ATV Entrepreneurs VII, L.P. ("ATV VII E"), respectively. Shares ultimately received by each of these entities were net of shares withheld, as described in footnote 3, due to the net exercise of warrants.

F2 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
December 07, 2016 Filed Dec 19, 2016 16:05 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Tax withholdingCommon Stock 22,000 $33.98 $747,560.00
Disclosure

SEC source: 0001209191-16-155873 · doc4.xml · nonDerivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 105,122

F3 · shares: Represents 20,648 shares, 829 shares, 399 shares and 124 shares of common stock withheld in connection with the net exercise of warrants by ATV VII, ATV VII B, ATV VII V and ATV VII E, respectively. Such shares were withheld by the issuer in satisfaction of the warrants' exercise price and did not involve the sale of shares by the holders.

F2 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
December 07, 2016 Filed Dec 19, 2016 16:05 UTC ACCELERON PHARMA INC XLRN · Entity 15780 Exercise / conversionCommon Stock 127,122 $5.88 $747,477.36
Disclosure

SEC source: 0001209191-16-155873 · doc4.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 127,122

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents 119,322 shares, 4,788 shares, 2,301 shares and 711 shares of common stock underlying warrants held by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C") and ATV Entrepreneurs VII, L.P. ("ATV VII E"), respectively. Shares ultimately received by each of these entities were net of shares withheld, as described in footnote 3, due to the net exercise of warrants.

F2 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
November 17, 2016 Filed Nov 18, 2016 16:34 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 379,464 $38.05 $14,438,605.20
Disclosure

SEC source: 0001209191-16-151236 · doc4.xml · nonDerivative · entry 3

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F9 · shares: Represents 355,491 shares, 14,265 shares, 6,857 shares, 2,118 shares and 733 shares that were held directly, and sold, by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

F4 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

F5 · ownership.nature: ATV Alliance Associates, L.L.C. ("ATV Alliance LLC") is the general partner of ATV 2003 and exercises voting and dispositive authority over the shares held by ATV 2003. Voting and dispositive decisions of ATV Alliance LLC are made by Ms. George. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
November 17, 2016 Filed Nov 18, 2016 16:34 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 41,112 $39.13 $1,608,712.56
Disclosure

SEC source: 0001209191-16-151236 · doc4.xml · nonDerivative · entry 2

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 379,464

F6 · shares: Represents 38,515 shares, 1,546 shares, 743 shares, 229 shares and 79 shares that were held directly, and sold, by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

F7 · price: Represents weighted average price. The shares were sold at prices ranging from $39.05 to 39.56. The reporting person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F8 · balance_after: Represents 355,491 shares, 14,265 shares, 6,857 shares, 2,118 shares and 733 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

F4 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

F5 · ownership.nature: ATV Alliance Associates, L.L.C. ("ATV Alliance LLC") is the general partner of ATV 2003 and exercises voting and dispositive authority over the shares held by ATV 2003. Voting and dispositive decisions of ATV Alliance LLC are made by Ms. George. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
November 16, 2016 Filed Nov 18, 2016 16:34 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 32,929 $41.39 $1,362,931.31
Disclosure

SEC source: 0001209191-16-151236 · doc4.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 420,576

F1 · shares: Represents 30,849 shares, 1,238 shares, 595 shares, 184 shares and 63 shares that were held directly, and sold, by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C"), ATV Entrepreneurs VII, L.P. ("ATV VII E") and ATV Alliance 2003, L.P. ("ATV 2003"), respectively.

F2 · price: Represents weighted average price. The shares were sold at prices ranging from $41.31 to $41.47. The reporting person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: Represents 394,006 shares, 15,811 shares, 7,600 shares, 2,347 shares and 812 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

F4 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

F5 · ownership.nature: ATV Alliance Associates, L.L.C. ("ATV Alliance LLC") is the general partner of ATV 2003 and exercises voting and dispositive authority over the shares held by ATV 2003. Voting and dispositive decisions of ATV Alliance LLC are made by Ms. George. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document
September 30, 2016 Filed Oct 4, 2016 19:37 UTC ACCELERON PHARMA INC XLRN · Entity 15780 SaleCommon Stock 857,145 $35.50 $30,428,647.50
Disclosure

SEC source: 0001209191-16-144718 · doc4.xml · nonDerivative · entry 1

George Jean · CIK 0001291804 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 453,505

F1 · shares: Represents 802,998 shares, 32,222 shares, 15,489 shares, 4,783 shares and 1,653 shares that were held directly, and sold, by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C"), ATV Entrepreneurs VII, L.P. ("ATV VII E") and ATV Alliance 2003, L.P. ("ATV 2003"), respectively.

F2 · balance_after: Represents 424,855 shares, 17,049 shares, 8,195 shares, 2,531 shares and 875 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

F3 · ownership.nature: ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

F4 · ownership.nature: ATV Alliance Associates, L.L.C. ("ATV Alliance LLC") is the general partner of ATV 2003 and exercises voting and dispositive authority over the shares held by ATV 2003. Voting and dispositive decisions of ATV Alliance LLC are made by Ms. George. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.